Gene Therapy Quality Assurance
and GMP Compliance Consulting

Comprehensive quality assurance for AAV gene therapy and viral vector programs, from QMS design and GMP compliance through adventitious agent testing strategies, vector shedding protocols, and BLA-ready quality systems.

scientist Analytical Method

Support Across All Stages Ensuring Compliance and Product Integrity for Gene Therapy

DES Pharma provides comprehensive quality assurance to ensure patient safety across all stages of drug development. Our team confirms that every gene therapy program adheres to regulatory standards, maintains viral vector product integrity, and delivers integrated quality oversight across the entire product lifecycle.

Gene therapy QA requires specialized expertise beyond standard biologic quality systems, including adventitious agent testing programs, vector shedding study design, genotoxicity risk assessments, and CBER-specific inspection readiness strategies that conventional QA frameworks do not address.

🛡️

Gene Therapy-Specific Compliance Services

Specialized QA capabilities for AAV gene therapy and viral vector regulatory compliance

This includes adventitious agent testing program design (ICH Q5A(R2), 21 CFR 610, USP <71>), vector shedding protocols for clinical and post-marketing studies, and GMP quality system development aligned with CBER expectations for viral vector manufacturing. We bridge the gap between standard biologic QA and the heightened expectations of gene therapy regulation.

🚀 Adventitious Agent Testing Program Design
🚀 Vector Shedding Protocol Development
🚀 CBER-Aligned GMP Quality System Design
🚀 Genotoxicity Risk Assessment Frameworks
🚀 Gene Therapy CAPA System Implementation
🚀 FDA CBER Inspection Readiness
🚀 ICH Q5A(R2) Compliance Gap Assessment
🚀 IND / BLA CMC Quality Section Review

Our Quality Approach Smart, Efficient QA Operations
for Viral Vector Programs

We deliver value through operational efficiency, a streamlined approach to gene therapy quality assurance that prioritizes critical quality activities directly impacting patient safety and robust product supply.

Supplier Management & Qualification

Auditing & Assessment Systems

Material Quality Management

Manufacturing Operations QA

Supporting Reliable Outcomes Robust QA Processes Across
All Operations

Technical Operations

CMC documentation review, analytical method lifecycle management, and technical operations qualification

QC Operations

Laboratory document review, deviation and OOS investigation management, and data integrity assessments (21 CFR Part 11)

Product Release

Batch release approval, specification and COA review, Product Quality Review (PQR), and Annual Product Review (APR)

Gene Therapy-Specific

Adventitious agent testing, vector shedding protocols, genotoxicity risk, and CBER-specific compliance oversight

Gene Therapy QA Expertise Specialized Compliance for Viral Vector Programs

Gene therapy quality assurance is categorically distinct from conventional biologic QA. AAV programs face unique compliance requirements: from the design of adventitious agent testing panels aligned with ICH Q5A(R2) to the development of vector shedding study protocols that meet FDA and EMA post-marketing expectations, to the genotoxicity risk frameworks required by CBER.

DES Pharma’s QA consultants have built quality systems specifically for gene therapy programs, understanding the intersection of viral vector biology, manufacturing complexity, and regulatory expectations. We help gene therapy companies build quality cultures and systems that hold up under CBER pre-approval inspections, avoiding the delays that poorly designed gene therapy QA programs consistently produce.

Whether you need to design your first GMP-compliant QMS, prepare for a CBER audit, or develop a vector shedding risk assessment for your clinical program, DES Pharma delivers the specialized quality expertise to keep your gene therapy program compliant and on track.

Adventitious Agent Testing Program Design

ICH Q5A(R2) compliant testing strategy including in-vitro and in-vivo assays, PCR-based screening, and cell-based detection methods for AAV manufacturing

Vector Shedding Protocol Development

FDA- and EMA-aligned shedding study designs for clinical trials and post-marketing commitments: sample collection strategy, assay selection, and data interpretation frameworks

Genotoxicity & Insertional Mutagenesis Risk

Risk-based framework development for integration site analysis, long-term follow-up (LTFU) study design, and regulatory justification for AAV genotoxicity risk assessment

FDA CBER Inspection Readiness

Mock PAI assessments, CBER-specific inspection preparation, prior approval supplement (PAS) strategy, and FDA response support for gene therapy manufacturing

IND / BLA Quality Section Authorship

CMC quality narrative development, quality overall summary (QOS), and CBER-aligned QA section documentation for gene therapy IND and BLA submissions

Key Regulatory Framework Gene Therapy QA Regulatory
Reference Guide

Critical regulatory requirements that define the compliance framework for AAV gene therapy quality systems, each requiring specialized expertise beyond standard biologic QA.

Regulatory Requirement Guideline / Reference Gene Therapy Significance Type
Adventitious Agent Testing ICH Q5A(R2); 21 CFR 610; USP <71> Mandatory for all viral vector cell substrates and production processes, more extensive than standard biologics Required
Vector Shedding Studies FDA CBER Guidance 2015; EMA Guideline 2009 Clinical and post-marketing studies to assess patient-to-patient transmission risk via body fluids Required
Long-Term Follow-Up (LTFU) FDA CBER Guidance 2020 (GT LTFU) 15-year patient monitoring program required for integrating gene therapies; AAV risk stratification may reduce duration Required
Genotoxicity / Insertional Risk FDA 2006 GTGTF; EMA Guideline EMEA/236981 Risk-based assessment required; AAV generally considered low integration risk but documentation required GT-Specific
Replication Competent Virus (RCV) FDA CBER Guidance; ICH Q5A RCV assays required for every AAV lot to confirm absence of replication-competent particles Required
Cell Substrate Qualification ICH Q5B; ICH Q5D; USP <1010> MCB/WCB characterization and qualification required for HEK293, Sf9, and other cell substrates used in AAV manufacturing Required
Data Integrity (GMP) 21 CFR Part 11; FDA DI Guidance 2018; EMA ANNEX 11 Electronic records and signatures requirements for all GMP data generated during viral vector manufacturing and testing Required

Our Quality MethodologyHow We Build Gene Therapy
Quality Systems That Last

A four-step approach to building quality systems that are both compliant and
operationally sustainable for gene therapy programs.

Quality Risk Assessment

Begin with ICH Q9-based risk assessment of your specific gene therapy product, manufacturing platform, and regulatory pathway to identify the highest-priority quality system gaps.

Phase-Appropriate QMS Design

Build quality systems calibrated to your development stage: IND-enabling QA has different requirements than PPQ-stage or BLA commercial quality systems.

Gene Therapy-Specific Protocol Development

Design and execute adventitious agent testing, vector shedding, and genotoxicity risk protocols that meet FDA CBER and EMA expectations for viral vector products.

Inspection Readiness & BLA Support

Prepare for CBER pre-approval inspections, author quality sections for regulatory submissions, and ensure your QA documentation package supports BLA approval.

Get Started Build a CBER-Ready Gene
Therapy Quality System

Ensure your AAV program meets FDA and EMA compliance
expectations at every stage.